secwatch.observer — SEC 8-K summary
======================================

Issuer:     Equillium, Inc. (EQ)
CIK:        0001746466
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0000950170-25-045723
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Equillium Reports Q4 and Full Year 2024 Financial Results and Provides Clinical Updates
--------------------------------------------------------------------------------

- Phase 3 EQUATOR study in aGVHD: primary endpoint not met, but statistically significant longer-term outcomes (CR at Day 99, duration of CR, failure-free survival).
- Full year 2024 revenue $41.1M, up from $36.1M in 2023; net loss $8.1M ($0.23/share) vs $13.3M ($0.38/share) in 2023.
- Cash and investments $22.6M as of Dec 31, 2024; expected to fund operations into Q3 2025.
- FDA meeting requested for Accelerated Approval of itolizumab in aGVHD; feedback expected May 2025.
- Positive Phase 2 data for itolizumab in ulcerative colitis: clinical remission rate 23.3% vs 10.0% placebo at 12 weeks.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746466/000095017025045723/0000950170-25-045723-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746466/000095017025045723/eq-20250327.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-045723

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer